Rufinamide (Standard)

Rufinamide (Standard) is the analytical standard of Rufinamide (HY-A0042) . This product is intended for research and analytical applications. Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome[1][2][3][4].

Product Specifications

CAS Number

[106308-44-5]

Product Name Alternative

CGP 33101 (Standard) ; E 2080 (Standard) ; RUF 331 (Standard)

UNSPSC

12352005

Hazard Statement

H336-H351-H361

Target

Reference Standards; Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Others

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/rufinamide-standard.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=CN(CC2=C(F)C=CC=C2F)N=N1)N

Molecular Formula

C10H8F2N4O

Molecular Weight

238.19

Precautions

P261-P271-P280-P304+P340-P403+P233-P405-P501

References & Citations

[1]Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118 (1) :160-72.|[2]Chen JL, et.al. Inhibition of resurgent Na+ currents by rufinamide. Neuropharmacology. 2024 Apr 1;247:109835.|[3]White HS, et.al. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49 (7) :1213-20.|[4]Suter MR, et.al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118 (1) :160-72.